Current epidemiology of diabetic retinopathy and diabetic macular edema

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 346-354

  Ding, Jie ^a,b,c   Wong, Tien Yin ^a,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Epidemiology; Risk factors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN;

AKR1B1 GENE; ARTICLE; CYTOKINE PRODUCTION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SURVEILLANCE; DYSLIPIDEMIA; EARLY DIAGNOSIS; GENE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MASS SCREENING; OBESITY; POPULATION RISK; PREGNANCY OUTCOME; PROTEIN EXPRESSION; PUBERTY; RISK ASSESSMENT; RISK FACTOR;

APOLIPOPROTEINS; BLINDNESS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACULAR EDEMA; MALE; MASS SCREENING; OBESITY; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 84865589092     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0283-6     Document Type: Article

References (91)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;10(376):124-36.
2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. A meta-analysis of individual participant data on the prevalence and major risk factors of diabetic retinopathy.
3. Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556-62.
4. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304:649-56.
5. Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26:1731-37. (Pubitemid 36929112)
6. Raymond NT, Varadhan L, Reynold DR, et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: A cross-sectional study. Diabetes Care. 2009;32:410-15.
7. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: The Handan Eye Study. Ophthalmology. 2009;116:461-67.
8. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006.
9. Graefes Arch Clin Exp Ophthalmol. 2008;246:1519-26.
10. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: The Singapore Malay EyeStudy. Ophthalmology. 2008;115:1869-75.
11. Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328-33. (Pubitemid 43119476)
12. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228-36.
13. Klein R. The epidemiology of diabetic retinopathy. In: Duh E, editor. Diabetic retinopathy. Totowa: Humana Press; 2008. p. 67-108.
14. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
15. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859-68.
16. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
17. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a populationbased screening program in England. Diabetes Care. 2012;35:592-96.
18. Klein R, Klein BE. Are individuals with diabetes seeing better? A long-term epidemiological perspective. Diabetes. 2010;59:1853-60.
19. Lecaire T, Palta M, Zhang H, et al. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes: The Wisconsin Diabetes Registry Study. Am J Epidemiol. 2006;164:143-50. (Pubitemid 43992180)
20. Cugati S, Kifley A, Mitchell P, Wang JJ. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: Population-based survey findings. Diabetes Res Clin Pract. 2006;74:301-8. (Pubitemid 44604313)
21. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21:1230-5. (Pubitemid 28365675)
22. Olsen BS, Sjølie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications. 2004;18:160-4. (Pubitemid 38622544)
23. Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetic complications? Diabetes Care. 2003;26:1224-9. (Pubitemid 36929276)
24. Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care. 1990;13:1034-38. (Pubitemid 20333923)
25. Sultan MB, Starita C, Huang K. Epidemiology, risk factors and management of paediatric diabetic retinopathy. Br J Ophthalmol. 2012;96:312-7.
26. Vestgaard M, Ringholm L, Laugesen CS, et al. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med. 2010;27:431-5.
27. Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010;53:1076-83.
28. Sheth BP. Does pregnancy accelerate the rate of progression of diabetic retinopathy? An update. Curr Diab Rep. 2008;8:270-3.
29. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care. 2000;23:1084-91.
30. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18:631-37.
31. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA. 2007;298:902-16. (Pubitemid 47311296)
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
33. The Diabetes Control and ComplicationsTrial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-9.
34. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874-86.
35. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707-15.
36. Wong TY, Liew G, Tapp RJ. Relation between fasting glucose and retinopathy for diagnosis of diabetes: Three population-based crosssectional studies. Lancet. 2008;371:736-43. (Pubitemid 351288874)
37. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
38. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. (Pubitemid 351831356)
39. Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ. 2009;338:b441.
40. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
41. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: Prospective cohort study. BMJ. 2008;337:a918.
42. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Longterm follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-76.
43. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet. 2008;372:1361-63.
44. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet. 2008;372:1394-402.
45. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet. 2008;372:1385-93.
46. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
47. Raman R, Rani PK, Kulothungan V. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117:766-72.
48. Rema M, Srivastava BK, Anitha B, et al. Association of serum lipids with diabetic retinopathy in urban South Indians -the Chennai Urban Rural Epidemiology Study (CURES) Eye Study -2. Diabet Med. 2006;23:1029-36. (Pubitemid 44257950)
49. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910-18. (Pubitemid 38868391)
50. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446-55.
51. Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabeticmacular edema. Invest Ophthalmol Vis Sci. 2011;52:7464-9.
52. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet. 2007;370:1687-97. (Pubitemid 350100775)
53. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-44.
54. Cheung N,Wong TY. Fenofibrate and diabetic retinopathy. Lancet. 2008;371:721-2. (Pubitemid 351288864)
55. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52:180-95. (Pubitemid 46371493)
56. Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci. 2011;52:4416-21.
57. Chaturvedi N, Sjoelie AK, Porta M. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284-9. (Pubitemid 32119126)
58. Henricsson M, Nyström L, Blohmé G. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003;26:349-54. (Pubitemid 36929054)
59. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527-32. (Pubitemid 14127839)
60. Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4458-63.
61. Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157:650-6. (Pubitemid 27133195)
62. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910-8. (Pubitemid 38868391)
63. Simo R, Garcia-Ramirez M, Higuera M, Hernandez C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol. 2009;147:319-25. e311.
64. Simó R, Higuera M, García-Ramírez M. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol. 2008;126:1076-81.
65. Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:2679-85.
66. Davidson MH. Apolipoprotein measurements: Is more widespread use clinically indicated? Clin Cardiol. 2009;32:482-6.
67. Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011;34:474-79.
68. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343-58.
69. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52-9.
70. Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes -the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-78. (Pubitemid 40543311)
71. Nguyen TT, Alibrahim E, Amirul Islam F. Inflammatory, hemostatic and other novel biomarkers for diabetic retinopathy: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2009;32:1704-9.
72. Yilmaz T, Weaver CD, Gallagher MJ. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: A systematic review. Ophthalmology. 2009;116:902-11. quiz 912-3.
73. Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245-51.
74. Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (e35). Ophthalmology. 2010;117:1064-77.
75. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14.
76. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. (e1-10). Ophthalmology. 2008;115:1447-9.
77. Ip MS, Bressler SB, Antoszyk AN, et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: Baseline features. Retina. 2008;28:919-30.
78. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405.
79. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
80. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25.
81. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49:35-52.
82. Hallman DM, Huber Jr JC, Gonzalez VH, et al. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005;28:1163-8. (Pubitemid 40616629)
83. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46:1829-39.
84. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57:2176-80.
85. Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: The FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49:3839-45.
86. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic metaanalysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58:2137-47.
87. Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: The Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52:7593-602.
88. Grassi MA, Tikhomirov A, Ramalingam S. Genome-wide metaanalysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20:2472-81.
89. Grassi MA, Tikhomirov A, Ramalingam S, et al. Replication analysis for severe diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012 Mar 16. [Epub ahead of print]
90. Thomas RL, Dunstan F, Luzio SD. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attendingthe Diabetic Retinopathy Screening Service for Wales: Retrospective analysis. BMJ. 2012;344:e874. doi:10.1136/bmj.e874.
91. Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: A cohort study. Lancet. 2003;361:195-200. (Pubitemid 36126218)